Polifarmacija i rizik od lek-lek interakcija kod pacijenata sa reumatoidnim artritisom
Sažetak
Cilj studije je bio da se utvrdi učestalost polifarmacije i ispita njen uticaj na rizik od lek-lek interakcija kod pacijenata sa reumatoidnim artritisom (RA). Istraživanje je sprovedeno u vidu retrospektivne studije preseka. Studijom je obuhvaćen 131 pacijent sa dijagnozom RA, lečenih tokom 2019. i 2020. godine. Demografski podaci i kliničke karakteristike pacijenata prikljupljeni su iz medicinske dokumentacije (prisustvo komorbiditeta, propisana terapije i broj lekova). U ovoj studiji polifarmacija je definisana kao upotreba više od 5 lekova, bez obzira na dužinu terapije. Analiza podataka o terapiji koju su pacijenti primenjivali pokazala je da je 84 ispitanika (64,12%) primenjivalo 6-10 lekova, kako za lečenje primarnih tako i za lečenje drugih prisutnih akutnih i hroničnih bolesti. Analizom prikupljenih rezultata identifikovane su potencijalne interakcije kod 86 ispitanika (65,65%), dok je ukupan broj potencijalnih interakcija bio 164. Najčešće potencijalne interakcije su bile ozbiljne (73,78%). Analizom dobijenih rezultata, proizilazi da je aceklofenak lek koji ima potencijal da stupi u najveći broj interakcija sa lekovima koji se koriste u terapiji RA. S obzirom na širok spektar dostupnih lekova i terapijskih modaliteta koji se koriste u lečenju RA, neophodno je odabrati pravu kombinaciju lekova, u cilju ostvarivanja željenih terapijskih ishoda i minimiziranja potencijalnih lek-lek interakcija.
Reference
1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376(9746):1094-108.
2. Stojanović S, Stamenković B, Nedović J, Aleksić I, Cvetković J. Effectiveness of Tocilizumab after Switching from Intravenous to Subcutaneous Formulation in Patients with Rheumatoid Arthritis: A Single-Centre Experience. Acta Facultatis Medicae Naissensis 2021; 38(3): 247-56.
3. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59(6): 762-84.
4. Bagatini F, Blatt RC, Maliska G, Trespash VG, Pereira AI, Zimmermann FA, et al. Potential drug interactions in patients with rheumatoid arthritis. Rev Bras Reumatol. 2011; 51(1): 20-39.
5. National Center for Health Statistics. Healthy People 2000 Final Review. Hyattsville, Maryland: Public Health Service; 2001. DHHS Publication No. 01-0256.
6. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17(1):230.
7. Pflugbeil S, Böckl K, Pongratz R, Leitner M, Graninger W, Ortner A. Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis. Rheumatol Int. 2020; 40: 511–21.
8. Zelko E, KlemencKetis Z, TusekBunc K. Medication adherence in elderly with polypharmacy living at home: a systematic review of existing studies. Mater SocioMed. 2016; 28:129–32.
9. Softic N, Smogavec M, Klemenc-Ketis Z, Kersnik J. Prevalence of chronic diseases among adult Slovene population. Zdrav Var. 2011; 50: 185-90.
10. Pivec N, Serdinsek T, Klemenc-Ketis Z, Kersnik J. Prevalence of disease symptoms in slovenian adult population and factors associated with their prevalence. Zdrav Var. 2014; 53: 262-9.
11. Menditto E, Miguel AG, Juste AM, Plou BP, Pascual-Salcedo MA, Orlando V, et al. Patterns of multimorbidity and polypharmacy in young and adult population: Systematic associations among chronic diseases and drugs using factor analysis. Systematic associations among chronic diseases and drugs using factor analysis. PLoS ONE 14(2): e0210701.
12. Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. Journal of Comorbidity 2011; 1: 28–44.
13. Zhang N, Sundquist J, Sundquist K, Ji J. An Increasing Trend in the Prevalence of Polypharmacy in Sweden: A Nationwide Register-Based Study. Front Pharmacol. 2020; 11: 326.
14. Milton JC, Hill-Smith I, Jackson SHD. Prescribing for older people. BMJ 2008; 336(7644): 606–9.
15. Caughey GE, Roughead EE, Pratt N, Shakib S, Vitry AI, Gilbert AL. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiol Drug Saf. 2010; 19(9): 977–82.
16. Caughey GE, Roughead EE, Vitry AI, McDermott RA, Shakib S, Gilbert AL. Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Pract. 2010; 87(3) :385–93.
17. Hermann M, Carstens N, Kvinge L, Fjell A, Wennersberg M, Folleso K, et al. Polypharmacy and Potential Drug–Drug Interactions in Home-Dwelling Older People – A Cross-Sectional Study. Journal of Multidisciplinary Healthcare 2021; 14: 589-97.
18. Krstić N, Stefanović N, Gocić V, Ilić K, Damnjanović I. Influence of polypharmacy on the functional ability of patients with rheumatoid arthritis. Acta Medica Medianae 2022; 61(4): 24-30.
19. Bagatini F, Blatt CR, Maliska G, Trespash GV, Pereira IA, Zimmermann AF, et al. Potential drug interactions in patients with rheumatoid arthritis. Rev Bras Reumatol. 2011; 51(1): 20-39.
20. Gomides AP, Alburquerque CP, Santos ABV, Amorim RBC, Bertolo MB, Junior PL, et al. High Levels of Polypharmacy in Rheumatoid Arthritis—A Challenge Not Covered by Current Management Recommendations: Data From a Large Real-Life Study.Journal of Pharmacy Practice 2021; 34(3): 365-71.
21. Ma SN, Huri HZ, Yahya F. Drug-related problems in patients with rheumatoid arthritis.Therapeutics and Clinical Risk Management 2019;15: 505–24.
22. Pflugbeil S, Böckl K, Pongratz R, Leitner M, Graninger W, Ortner A. Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis. Rheumatology International 2020.
23. Colebatch AN, Marks JL, van der Heijde DM, Edwards CJ. Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. Journal of Rheumatology Supplement 2012; 90: 62–73.
24. Arava (Leflunomide), Sanofi-Aventis. UK Summary of product characteristics, September 2009.
25. EMEA, “EMEA public statement on leflunomide (Arava)— severe and serious hepatic reactions,” London, UK, March 2001, http://www.emea.europa.eu/docs/en GB/document library/ Public statement/2009/12/WC500018389.pdf.
26. Hill RL, Topliss DJ, Purcell PM. Pancytopenia associated with leflunomide and methotrexate. Annals of Pharmacotherapy 2003; 37(1): 149.
27. McEwen J, Purcell PM, Hill RL, Calcino LJ, Riley CG. The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate. Pharmacoepidemiology and Drug Safety 2007; 16(1): 65–73.
28. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases 2009; 68 (7): 1105–12.
29. Simponi (Golimumab), Centocor Ortho Biotech Inc. US Prescribing information, April 2009.
30. Davies B, Shaw T. Rituximab pharmacokinetic characteristics are not influenced by combination with methotrexate or cyclophosphamide. Annals of the Rheumatic Diseases 2004; 63: FRI0128.
31. CRA Pharmacist Highlights June 2015 [Internet]. 2015 [cited 2023 Aug 7]. Available from: https://rheum.ca/wp-content/uploads/2017/11/CRA_Pharmacist_Highlights_June_2015_CT.pdf
32. Katchamart W, Bourré-Tessier J, Donka T, Drouin J, Rohekar G, Bykerk VP, et al. Canadian recommendations for the use of methotrexate in patients with rheumatoid arthritis. J Rheumatol 2010; 37: 1422-30.
33. New Safety Information: Interaction of Proton Pump Inhibitors (PPIs) with Methotrexate [Internet]. 2012 [cited 2023 Aug 7]. Available from: https://recalls-rappels.canada.ca/en/alert-recall/new-safety-information-interaction-proton-pump-inhibitors-ppis-methotrexate
34. Bornstein C, Craig M, Tin D. Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada. 2014: 147(2): 97–109.
35. Kojima G, Bell C, Tamura B, Inaba M, Lubimir K, Blanchette PL, et al. Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. J Am Med Dir Assoc 2012; 13: 818.e11–5.